drugset
drugset / Trial / NCT05653323

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

NCT05653323 ↗

Phase 1 Completed 70 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-993 at different doses in healthy participants.

Timeline

Start
2022-12-14
Primary completion
2023-09-12
Completion
2023-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VX-993 Unknown — Oral

Indications

No indication recorded.